JPMorgan CEO says 'it's time to fight back' on regulation-February 2024-www.financetom.com

JPMorgan CEO says 'it's time to fight back' on regulation

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

JPMorgan CEO says 'it's time to fight back' on regulation

Nov 3, 2024 12:45 PM

NEW YORK, Oct 28 (Reuters) - JPMorgan Chase ( JPM ) CEO Jamie

Dimon blasted several major regulatory initiatives on capital

rules, card payments and open banking at a conference on Monday.

Previous page： AG Mortgage Q3 gets boost from increased Arc Home stake Next page： Wright Flood completes the acquisition of Poulton Associates, LLC

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

AG Mortgage Q3 gets boost from increased Arc Home stake

Nov 4, 2025

Overview * AG Mortgage Q3 net income was $0.47 per share * Company acquired additional 21.4% interest in Arc Home, increasing ownership to 66% * Earnings available for distribution were $0.23 per share, supported by Arc Home's contribution Outlook * Company did not provide specific guidance for future quarters Result Drivers * ARC HOME CONTRIBUTION - Increased stake in Arc...

Wright Flood completes the acquisition of Poulton Associates, LLC

Nov 4, 2025

CLEARWATER, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wright National Flood Insurance Company (“Wright Flood”) today announced the completion of the previously announced acquisition of the insurance operations Poulton Associates, LLC. About Wright National Flood Insurance Company Wright Flood, a wholly owned subsidiary of Brown & Brown Inc. ( BRO ), operating within Arrowhead Programs, is the largest flood insurance...

Kura Oncology Q3 net loss widens to $74.1 mln

Nov 4, 2025

Overview * Kura Oncology reports Q3 2025 net loss of $74.1 mln, up from $54.4 mln in 2024 * Collaboration revenue for Q3 2025 was $20.8 mln, compared to none in Q3 2024 * Company's ziftomenib program under FDA Priority Review, PDUFA date set for Nov 30, 2025 Outlook * Kura Oncology ( KURA ) expects FDA decision on ziftomenib...

TopBuild Reports Third Quarter 2025 Results; Raises Guidance to Include Recent Acquisitions

Nov 4, 2025

Delivers third quarter sales of $1.4 billion and adjusted EBITDA margin of 19.8% Raises 2025 outlook to $5.35 to $5.45 billion in sales and $1.01 to $1.06 billion in adjusted EBITDA, to include contribution from SPI and four recent acquisitions DAYTONA BEACH, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TopBuild Corp. ( BLD ) , a leading installer of insulation...